Cormorant Asset Management »

Arrivent Biopharma shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Arrivent Biopharma shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $9.2M 515k 17.86

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Eyepoint Pharmaceuticals Com New (EYPT)
Arcellx Common Stock (ACLX)
Alpine Immune Sciences (ALPN)
Bridgebio Pharma (BBIO)
Praxis Precision Medicines I Com New (PRAX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Tarsus Pharmaceuticals (TARS)
Longboard Pharmaceuticals In (LBPH)
Edgewise Therapeutics (EWTX)
Crinetics Pharmaceuticals In (CRNX)
Biomea Fusion (BMEA)
Korro Bio (KRRO)
Vaxcyte (PCVX)
Autolus Therapeutics Spon Ads (AUTL)

View all positions for Cormorant Asset Management

Top funds holding Arrivent Biopharma

OrbiMed Advisors
FMR
Octagon Capital Advisors
Sofinnova Ventures
Suvretta Capital Management
General Catalyst Group Management
Sc China Holding
BlackRock
Vanguard Group
Cormorant Asset Management
Perceptive Advisors
Citadel Advisors
Geode Capital Management
Millennium Management
Farallon Capital Management

View all funds holding Arrivent Biopharma